- Home
- CNNE vs AKBA Comparison
CNNE vs AKBA Comparison
Compare CNNE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- AKBA
- Stock Information
- Founded
- CNNE 2014
- AKBA 2007
- Country
- CNNE United States
- AKBA United States
- Employees
- CNNE N/A
- AKBA N/A
- Industry
- CNNE Restaurants
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- AKBA Health Care
- Exchange
- CNNE Nasdaq
- AKBA Nasdaq
- Market Cap
- CNNE 869.9M
- AKBA 729.1M
- IPO Year
- CNNE N/A
- AKBA 2014
- Fundamental
- Price
- CNNE $15.26
- AKBA $1.75
- Analyst Decision
- CNNE Buy
- AKBA Strong Buy
- Analyst Count
- CNNE 4
- AKBA 6
- Target Price
- CNNE $22.25
- AKBA $6.25
- AVG Volume (30 Days)
- CNNE 573.2K
- AKBA 5.7M
- Earning Date
- CNNE 11-10-2025
- AKBA 11-10-2025
- Dividend Yield
- CNNE 3.78%
- AKBA N/A
- EPS Growth
- CNNE N/A
- AKBA N/A
- EPS
- CNNE N/A
- AKBA N/A
- Revenue
- CNNE $430,200,000.00
- AKBA $225,071,000.00
- Revenue This Year
- CNNE N/A
- AKBA $53.38
- Revenue Next Year
- CNNE N/A
- AKBA $30.53
- P/E Ratio
- CNNE N/A
- AKBA N/A
- Revenue Growth
- CNNE N/A
- AKBA 32.49
- 52 Week Low
- CNNE $15.14
- AKBA $1.52
- 52 Week High
- CNNE $22.36
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- CNNE 25.31
- AKBA 30.26
- Support Level
- CNNE $15.14
- AKBA $1.57
- Resistance Level
- CNNE $16.26
- AKBA $1.89
- Average True Range (ATR)
- CNNE 0.67
- AKBA 0.15
- MACD
- CNNE -0.25
- AKBA -0.05
- Stochastic Oscillator
- CNNE 8.07
- AKBA 11.26
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.